Proactiveinvestors United Kingdom Mediclinic International Plc https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Mediclinic International Plc RSS feed en Mon, 22 Jul 2019 14:41:30 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190712123002_14147114/ Fri, 12 Jul 2019 12:30:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190712123002_14147114/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190701153001_14131912/ Mon, 01 Jul 2019 15:30:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190701153001_14131912/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190624120005_14121995/ Mon, 24 Jun 2019 12:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190624120005_14121995/ <![CDATA[RNS press release - Annual Financial Report ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190621150005_14120476/ Fri, 21 Jun 2019 15:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190621150005_14120476/ <![CDATA[RNS press release - Tax Treatment for South African Dividends ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190620140004_14118673/ Thu, 20 Jun 2019 14:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190620140004_14118673/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190618114843_14115238/ Tue, 18 Jun 2019 11:48:43 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190618114843_14115238/ <![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190523070004_14084339/ Thu, 23 May 2019 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190523070004_14084339/ <![CDATA[News - Mediclinic jumps as profit fall likely to be better-than-feared ]]> https://www.proactiveinvestors.co.uk/companies/news/218749/mediclinic-jumps-as-profit-fall-likely-to-be-better-than-feared-218749.html Private hospital operator Mediclinic International PLC (LON:MDC) has braced investors for a 3.5% fall in underlying profits when it publishes its full-year results in a month’s time.

But shares jumped 7% to 324.7p in early deals on Wednesday as the profit fall wasn’t as bad as analysts had feared.

READ: Mediclinic reports first-half profits drop

Underlying earnings (EBITDA) are expected to fall 3.5% year-on-year (2018: £515mln).

That is despite a 2.0% rise in revenue (2018: £2.87bn), with growth in all regions, including Switzerland, South Africa and the Middle East.

The drop-off in profitability comes amid a “challenging healthcare environment”, with regulatory changes in the Swiss healthcare market denting margins in that region by two percentage points.

Margins were also under pressure in the Southern Africa business, although they held steady in the Middle East.

Results in line with bosses’ expectations

As for Mediclinic’s share of the profits from its 29.9% stake in Spire Healthcare Group PLC (LON:SPI), that is expected to total £2.7mln (2018: £2.8mln).

“Our group results for the 2019 financial year were in line with market expectations in a challenging healthcare environment,” said chief executive Ronnie van der Merwe.

“I am encouraged by our operational progress this year, delivering on our strategic objectives. We executed against our growth strategy with investments across the continuum of care in all regions.”

Shares rose 5.5% to 320p in early deals on Wednesday.

-- Updates for share price --

]]>
Wed, 17 Apr 2019 08:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/218749/mediclinic-jumps-as-profit-fall-likely-to-be-better-than-feared-218749.html
<![CDATA[RNS press release - 2019 Full Year Trading Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190417070002_14043779/ Wed, 17 Apr 2019 07:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190417070002_14043779/ <![CDATA[RNS press release - Director Declaration ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190329110002_14021446/ Fri, 29 Mar 2019 11:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190329110002_14021446/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190129143001_13950683/ Tue, 29 Jan 2019 14:30:01 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190129143001_13950683/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190129133001_13950607/ Tue, 29 Jan 2019 13:30:01 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20190129133001_13950607/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181214130001_13904698/ Fri, 14 Dec 2018 13:00:01 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181214130001_13904698/ <![CDATA[RNS press release - Tax Treatment for South African Dividends ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181212120001_13901232/ Wed, 12 Dec 2018 12:00:01 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181212120001_13901232/ <![CDATA[RNS press release - Mediclinic Middle East Site Visit ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181212070002_13900079/ Wed, 12 Dec 2018 07:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181212070002_13900079/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181210133002_13897895/ Mon, 10 Dec 2018 13:30:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181210133002_13897895/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181120130002_13873797/ Tue, 20 Nov 2018 13:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181120130002_13873797/ <![CDATA[RNS press release - Director Declaration ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181120110002_13873561/ Tue, 20 Nov 2018 11:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181120110002_13873561/ <![CDATA[News - Mediclinic weak as first half profit falls due to a smaller contribution from its Swiss operation ]]> https://www.proactiveinvestors.co.uk/companies/news/209277/mediclinic-weak-as-first-half-profit-falls-due-to-a-smaller-contribution-from-its-swiss-operation-209277.html Mediclinic International Plc (LON:MDC) shares fell on Thursday as the firm saw its first-half profit decline due to a smaller contribution from its Swiss operation, Hirslanden.

The FTSE 250-listed private healthcare group saw its adjusted underlying earnings (EBITDA) fall by 8% to £213mln for the six months to September 30, down from £232mln a year earlier.

READ: Barclays has little confidence in the Mediclinic recovery story

The London and Johannesburg-quoted firm posted a pre-tax loss of £150mln in the first half, against a £10mln loss a year earlier, as revenue fell by 1.4% to £1.39bn from £1.41bn.

In Switzerland, the company’s adjusted EBITDA fell by 17% to SFr118mln despite revenue in the country rising by 1% to SFr826mln.

Mediclinic’s chief executive Ronnie van der Merwe commented: "The poor performance in Switzerland more than outweighed the revenue growth and margin expansion delivered by the Southern Africa and the Middle East divisions."

The group kept its interim dividend unchanged at 3.20p per share.

In early morning trading, Mediclinic shares were 3.9% lower at 341.40p.

In a separate announcement, Mediclinic also announced that its senior independent non-executive director Desmond Smith will retire from the board at the end of its annual general meeting expected to take place on 24 July 2019.

]]>
Thu, 15 Nov 2018 10:03:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/209277/mediclinic-weak-as-first-half-profit-falls-due-to-a-smaller-contribution-from-its-swiss-operation-209277.html
<![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181115070101_13867657/ Thu, 15 Nov 2018 07:01:01 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181115070101_13867657/ <![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181115070004_13867550/ Thu, 15 Nov 2018 07:00:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181115070004_13867550/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181107133000_13858764/ Wed, 07 Nov 2018 13:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181107133000_13858764/ <![CDATA[News - Barclays has little confidence in the Mediclinic recovery story ]]> https://www.proactiveinvestors.co.uk/companies/news/207370/barclays-has-little-confidence-in-the-mediclinic-recovery-story-207370.html Mediclinic International Plc (LON:MDC) shares were under pressure again on Thursday as Barclays downgraded the stock on the back of Wednesday’s disappointing interim trading update.

Shares in the private hospital operator nosedived yesterday after it reported a 10% fall in half-year underlying earnings (EBITDA) to £210mln (H1 17: £230mln).

The drop-off was primarily down to its Swiss subsidiary, Hirslanden, which was hit by “weaker than expected growth” in admissions and a higher proportion of insured patients.

READ: Mediclinic in red after write-downs at Spire and in Switzerland

Analysts at Barclays said the gloomy update left them “with less confidence in the recovery story” and they cut their rating to ‘equal weight’ (from ‘overweight’) as a result.

“We see downside to the updated full-year guidance and believe that sentiment will remain subdued until we see clear execution and improvement in the businesses,” read a note to clients.

The number crunchers added that Mediclinic will be “hard-pressed” to achieve a full-year margin of 16% in its Swiss business having only achieved 14.3% in the first half.

Over in the UAE, the company said on Wednesday that 2018/19 underlying earnings are “on-track”, but Barclays pointed out that first-half sales missed expectations while they “question the assumed recovery” in the second half.

The stock, which dropped 16.5% yesterday, was down another 4.5% to 376.5p in mid-morning on Thursday.

]]>
Thu, 18 Oct 2018 10:06:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207370/barclays-has-little-confidence-in-the-mediclinic-recovery-story-207370.html
<![CDATA[RNS press release - 2018/19 Interim Trading Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181017070004_13831389/ Wed, 17 Oct 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20181017070004_13831389/ <![CDATA[RNS press release - Combination - Hirslanden La Colline and Grangettes ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180904070004_13777400/ Tue, 04 Sep 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180904070004_13777400/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180814120001_13754945/ Tue, 14 Aug 2018 12:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180814120001_13754945/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180810140004_13751845/ Fri, 10 Aug 2018 14:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180810140004_13751845/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180726070004_13731705/ Thu, 26 Jul 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180726070004_13731705/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180725144502_13731313/ Wed, 25 Jul 2018 14:45:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180725144502_13731313/ <![CDATA[RNS press release - 2018 Capital Markets Day ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180628070005_13696539/ Thu, 28 Jun 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180628070005_13696539/ <![CDATA[RNS press release - South African B-BBEE Act: Annual Compliance Report ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180627120003_13695888/ Wed, 27 Jun 2018 12:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180627120003_13695888/ <![CDATA[RNS press release - Annual Financial Report ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180622150001_13690564/ Fri, 22 Jun 2018 15:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180622150001_13690564/ <![CDATA[RNS press release - Tax Treatment for South African Dividends ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180621143004_13689081/ Thu, 21 Jun 2018 14:30:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180621143004_13689081/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180618110001_13683487/ Mon, 18 Jun 2018 11:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180618110001_13683487/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180605120001_13667621/ Tue, 05 Jun 2018 12:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180605120001_13667621/ <![CDATA[RNS press release - Director Declaration ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180601070007_13662769/ Fri, 01 Jun 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180601070007_13662769/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180530150002_13660277/ Wed, 30 May 2018 15:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180530150002_13660277/ <![CDATA[News - Mediclinic in red after write-downs at Spire and in Switzerland ]]> https://www.proactiveinvestors.co.uk/companies/news/197630/mediclinic-in-red-after-write-downs-at-spire-and-in-switzerland-197630.html Hospital group Mediclinic International Plc (LON:MDC) plunged into the red on write-offs on investments in Switzerland and Spire Healthcare PLC (LON:SPI).

Mediclinic’s bid for the outstanding 70% of Spire was rejected by the UK healthcare group in November leading to the subsequent collapse of talks.

READ: Mediclinic nudges up guidance after strong second half for its Middle East division

Spire’s value had slumped after it paid out £37mln compensation to women treated by disgraced surgeon Ian Paterson.

South Africa-based Mediclinic, which runs hospitals in Africa, Switzerland and the Middle East,  posted a loss of £492mln in the year to March after a £109mln charge for Spire and £644mln at Swiss group Hirslanden.

Mediclinic also incurred £23mln of costs rebranding its Al-Noor acquisition.

Revenues over the year were 4% higher at £2.87bn with underlying profits 3% better at £515mln.

Shares fell 4% to 650p.

]]>
Thu, 24 May 2018 09:53:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197630/mediclinic-in-red-after-write-downs-at-spire-and-in-switzerland-197630.html
<![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180524070104_13653230/ Thu, 24 May 2018 07:01:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180524070104_13653230/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180524070014_13653179/ Thu, 24 May 2018 07:00:14 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180524070014_13653179/ <![CDATA[RNS press release - Appointment of Joint Corporate Broker ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180515070011_13640789/ Tue, 15 May 2018 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180515070011_13640789/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180508100001_13632634/ Tue, 08 May 2018 10:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180508100001_13632634/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180427171433_13622510/ Fri, 27 Apr 2018 17:14:33 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180427171433_13622510/ <![CDATA[News - Mediclinic nudges up guidance after strong second half for its Middle East division ]]> https://www.proactiveinvestors.co.uk/companies/news/195255/mediclinic-nudges-up-guidance-after-strong-second-half-for-its-middle-east-division-195255.html Mediclinic International Plc (LON:MDC), the international private healthcare services group, cheered the market Wednesday by raising profits guidance.

Driven by a significant second-half improvement from the group's Middle East division, management said the group expected to deliver adjusted financial results for the year to the end of March 2018 that are marginally ahead of expectations.

On a constant currency basis, revenue is expected to be up by around 2% year-on-year and adjusted underlying earnings (Ebitda) are expected to be flat.

Factoring in beneficial currency effects, revenue is expected to show a 4% increase to around £2.9bn and adjusted Ebitda by around 3% to £500mln or so.

"We are succeeding with the turnaround of the Abu Dhabi business and laying the foundation for long-term, sustainable performance,” claimed Danie Meintjes, the group's chief executive officer.

“The Middle East division is now entering an expansionary phase that we expect will drive a strong increase in revenue and improvement in margins over time. In Abu Dhabi, the growth will be driven by an improved operating performance in the existing business and strategic expansion projects at the Mediclinic Airport Road, Mediclinic Al Noor and the new Mediclinic Western Region hospitals,” Meintjes added.

In Dubai, the group expects that the ongoing performance of the existing business will be supported by significant growth from the new 182-bed Mediclinic Parkview Hospital, which is scheduled to open six months earlier than expected in October 2018.

There was also good news from South Africa, where the growth in revenues in the second half of the financial year just ended was ahead of expectations.

In Switzerland, the Hirslanden division performed in line with expectations as it began to absorb the initial impact of regulatory changes.

“The demand for the provision of quality healthcare services continues to increase driven by factors including an ageing population, growing disease burden and new technologies. Mediclinic, as the largest independent pan-EMEA private healthcare services group with market leading positions across all our operating divisions, is well positioned to benefit from these trends. Through our relentless focus on patient safety, excellent clinical performance, and sustainable and efficient operating practices, Mediclinic expects to continue to create long-term shareholder value," Meintjes said.

The shares were up 5.9% at 661.4p in lunchtime trading.

]]>
Wed, 18 Apr 2018 12:48:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195255/mediclinic-nudges-up-guidance-after-strong-second-half-for-its-middle-east-division-195255.html
<![CDATA[RNS press release - 2018 Full Year Trading Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180418070003_13608409/ Wed, 18 Apr 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180418070003_13608409/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180406120002_13595276/ Fri, 06 Apr 2018 12:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180406120002_13595276/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180329070011_13585995/ Thu, 29 Mar 2018 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20180329070011_13585995/ <![CDATA[RNS press release - Tax Treatment for South African Dividends ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20171213150002_13464428/ Wed, 13 Dec 2017 15:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20171213150002_13464428/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20171204143002_13453109/ Mon, 04 Dec 2017 14:30:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20171204143002_13453109/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20171128160001_13446714/ Tue, 28 Nov 2017 16:00:01 +0000 https://www.proactiveinvestors.co.uk/companies/rns/8356/LSE20171128160001_13446714/